Steve Gallagher, along with co-founder Alastair Hill, has taken Dotmatics from a scientific software start-up company to a multi-million dollar business supporting the world’s leading pharmaceutical, biotechnology and chemicals companies. Inspired by his experience as an end-user Data Scientist, Steve has always believed in providing researchers with access to all of their data, all of the time.
Co-founders Steve Gallagher and Alastair Hill worked together at Merck Pharmaceuticals (MSD) before founding Dotmatics in 2005, when Steve was appointed CEO.
Recognizing the need in scientific discovery for solutions that help manage large volumes of disparate data, Steve and Alastair developed a unique capability allowing scientists to access all relevant data in one interface.
Steve has generated a company culture of partnering with customers. Dotmatics consultants have the freedom to work closely with customers to characterize challenges and develop IT solutions specifically addressing scientific workflows.
In 2017 Steve agreed backing via growth equity firm Scottish Equity Partners, SEP (www.SEP.co.uk) to accelerate his strategic program. The most recent step, June 2020, involved the acquisition of BioBright, a scientific lab data automation company based in Boston to enable customers to automate their laboratory data workflows and provide a modern data foundation for their next generation scientific data management and AI/ML driven analytics. Dotmatics now has over 250 employees supporting global customers from corporate offices in the UK, Boston, San Diego, Tokyo and Seoul.
Steve founded Dotmatics following eight years’ industrial and academic experience. He provided research IT solutions to R&D teams as a Senior Systems Analyst at Merck Pharmaceuticals, MSD from 2000 to 2005. Prior to that Steve held a post-doctoral research position at Los Alamos Research Laboratory from 1997 to 2000 which reinforced his belief in the importance of collaborative research, across both geographies and domains. He holds a PhD in Biochemistry from the University of Warwick.
“A quote from Steve would go here about Dotmatics and why he started the company and how great his team is.”
Alastair Hill, along with co-founder Steve Gallagher, has taken Dotmatics from a scientific software start-up company to a multi-million dollar business supporting the world’s leading pharmaceutical, biotechnology and chemicals companies. Inspired by his experience as both a Medicinal Chemist and Cheminformatician, Alastair has long believed in the power of scientific informatics so it’s no surprise that he fully embraces the Dotmatics ‘mission’ to provide researchers with access to all of their data, all of the time.
Co-founders Alastair Hill and Steve Gallagher worked together at Merck Pharmaceuticals (MSD) before founding Dotmatics in 2005, when Alastair was appointed CTO.
Recognizing the need in scientific discovery for solutions that help manage large volumes of disparate data, Alastair and Steve developed a unique capability allowing scientists to access all relevant data in one interface.
Alastair’s technical expertise led the company to fully embrace Cloud informatics from inception. It would be several years before the majority of customers were actively seeking web-based cloud solutions as opposed to on-premise, both of which are supported. Alastair describes himself as an experienced technical pragmatist “In my view, the most successful technology strategy is one that is generally conservative, avoiding jumping on technical
bandwagons until they are proven, but prepared to make occasional wholesale changes when the business requires it.”
Alastair encourages tight interaction between Dotmatics and customers via customer advisory boards to ensure product development continues to align with client requirements, whether they are a smaller biotechnology company, top ten pharmaceutical or global chemicals organization. Prior to co-founding Dotmatics, Alastair worked at Merck Pharmaceuticals, MSD where he was responsible for developing chemical software applications and services for research scientists. He began his career with MSD in 1998 as a medicinal chemist before undertaking a Masters in Chemoinformatics at the University of Sheffield in 2002.